JP2009534312A5 - - Google Patents

Download PDF

Info

Publication number
JP2009534312A5
JP2009534312A5 JP2009504260A JP2009504260A JP2009534312A5 JP 2009534312 A5 JP2009534312 A5 JP 2009534312A5 JP 2009504260 A JP2009504260 A JP 2009504260A JP 2009504260 A JP2009504260 A JP 2009504260A JP 2009534312 A5 JP2009534312 A5 JP 2009534312A5
Authority
JP
Japan
Prior art keywords
propargyl
pharmaceutically acceptable
acceptable salt
aminoindan
aminoindane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009504260A
Other languages
English (en)
Japanese (ja)
Other versions
JP5769923B2 (ja
JP2009534312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/008261 external-priority patent/WO2007117431A2/en
Publication of JP2009534312A publication Critical patent/JP2009534312A/ja
Publication of JP2009534312A5 publication Critical patent/JP2009534312A5/ja
Application granted granted Critical
Publication of JP5769923B2 publication Critical patent/JP5769923B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009504260A 2006-04-03 2007-03-30 レストレスレッグス症候群の治療のためのラサギリンの使用 Expired - Fee Related JP5769923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78861706P 2006-04-03 2006-04-03
US60/788,617 2006-04-03
PCT/US2007/008261 WO2007117431A2 (en) 2006-04-03 2007-03-30 Use of rasagiline for the treatment of restless legs syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013087636A Division JP2013166772A (ja) 2006-04-03 2013-04-18 レストレスレッグス症候群の治療のためのラサギリンの使用

Publications (3)

Publication Number Publication Date
JP2009534312A JP2009534312A (ja) 2009-09-24
JP2009534312A5 true JP2009534312A5 (https=) 2010-05-13
JP5769923B2 JP5769923B2 (ja) 2015-08-26

Family

ID=38581572

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009504260A Expired - Fee Related JP5769923B2 (ja) 2006-04-03 2007-03-30 レストレスレッグス症候群の治療のためのラサギリンの使用
JP2013087636A Pending JP2013166772A (ja) 2006-04-03 2013-04-18 レストレスレッグス症候群の治療のためのラサギリンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013087636A Pending JP2013166772A (ja) 2006-04-03 2013-04-18 レストレスレッグス症候群の治療のためのラサギリンの使用

Country Status (11)

Country Link
US (16) US8946300B2 (https=)
EP (1) EP2007369A4 (https=)
JP (2) JP5769923B2 (https=)
CN (1) CN101442997B (https=)
AU (1) AU2007235517B2 (https=)
CA (1) CA2646250A1 (https=)
IL (5) IL194328A (https=)
MX (1) MX2008012781A (https=)
NZ (1) NZ571591A (https=)
WO (1) WO2007117431A2 (https=)
ZA (1) ZA200808409B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) * 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
CN101600346B (zh) * 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN102105169B (zh) 2008-06-06 2014-09-10 图必制药公司 用于治疗帕金森病的药物组合物
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド R(+)−n−メチル−プロパルギルアミノインダン
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
LT2802319T (lt) * 2012-01-12 2018-04-10 Pharma Two B Ltd. Fiksuotos dozės derinio terapija, skirta parkinsono ligai gydyti
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
JP7337081B2 (ja) * 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513249A (en) 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5444095A (en) 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5767164A (en) 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
EP0738149B1 (en) 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
AU2472499A (en) 1998-01-27 1999-08-09 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
JP2002507562A (ja) * 1998-03-27 2002-03-12 ファルマシア・アンド・アップジョン・カンパニー レストレスレッグ症候群の治療におけるカベルゴリンの使用
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US20040052843A1 (en) 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
JP2005523289A (ja) 2002-02-27 2005-08-04 テバ ファーマシューティカル インダストリーズ リミティド 脳選択性mao阻害剤としてのプロパルギルアミノインダン誘導体及びプロパルギルアミノテトラリン誘導体
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
JP2005060370A (ja) 2003-07-25 2005-03-10 Kyowa Hakko Kogyo Co Ltd 医薬組成物
US7735024B2 (en) 2003-10-29 2010-06-08 Intel Corporation Methods and apparatus to provide a handheld pointer-based user interface
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ATE521343T1 (de) 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CN101336109A (zh) 2005-12-20 2008-12-31 赛诺科学股份公司 用于治疗和诊断下肢不宁综合征的方法与组合物
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
CN101600346B (zh) 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
AU2008339607B2 (en) 2007-12-24 2012-08-02 Cipla Limited Process for the synthesis of propargylated aminoindan derivatives
EP2234478A4 (en) 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
US20110117200A1 (en) 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
MX2010013766A (es) 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CN101606923B (zh) 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
EA201170181A1 (ru) 2008-07-11 2011-08-30 Синтон Бв Полиморфные формы разагилина гидрохлорида
US20100041920A1 (en) 2008-07-18 2010-02-18 Stephen Benedict David Winter New salt forms of an aminoindan derivative
US20100029987A1 (en) 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
US20110263719A1 (en) 2008-07-30 2011-10-27 Vinayak Gore Polymorphic form of rasagiline mesylate
EP2181980A1 (en) 2008-10-28 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of (R)-1-aminoindanes
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
TW201028257A (en) * 2009-01-16 2010-08-01 Pao-Fang Liu Three-stage valve switch structure
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
US20110015274A1 (en) 2009-07-20 2011-01-20 Ester Masllorens Llinas Form of an aminoindan mesylate derivative
WO2011010324A1 (en) 2009-07-23 2011-01-27 Alkem Laboratories Ltd. Oral pharmaceutical composition of rasagiline and process for preparing thereof
AU2010304755A1 (en) 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
EP2621490A4 (en) 2010-09-29 2014-04-02 Teva Pharma PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF
SG189454A1 (en) 2010-10-26 2013-05-31 Teva Pharma Deuterium enriched rasagiline
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド R(+)−n−メチル−プロパルギルアミノインダン
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
AU2012323346A1 (en) 2011-10-10 2014-05-15 Teva Pharmaceutical Industries Ltd Rasagiline citramide
LT2802319T (lt) 2012-01-12 2018-04-10 Pharma Two B Ltd. Fiksuotos dozės derinio terapija, skirta parkinsono ligai gydyti
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Similar Documents

Publication Publication Date Title
JP2009534312A5 (https=)
RU2489155C2 (ru) Лечение нейродегенеративных заболеваний
JP2009280621A5 (https=)
JP2009532340A5 (https=)
JP2013507352A5 (https=)
JP2010500331A5 (https=)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2013533287A5 (https=)
JP2011527333A5 (https=)
NO20076134L (no) Benzamidderivater og anvendelser derav
JP2010514829A5 (https=)
JP2009538898A5 (https=)
FI3973959T3 (fi) Kolestaattisen kutinan hoito seladelpaarilla
JP2014511374A5 (https=)
JP2016503010A5 (https=)
MA34055B1 (fr) Chlorhydrate d'agomelatine hydrate et sa preparation
CO5840252A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada
JP2005523334A5 (https=)
JP2019052163A5 (https=)
JP2021073257A5 (https=)
BRPI0509976B8 (pt) uso de derivados de alfa-aminoamidas no tratamento de síndrome das pernas inquietas
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
WO2007107008A8 (en) Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
CY1113279T1 (el) Φαρμακευτικη συνθεση 271
JP2010539130A5 (https=)